The aim of this study was to describe @entity1863 disposition in a pediatric population who underwent bone marrow transplantation (BMT). @entity1863 administered dose was 1 mg/kg every 6 h for 4 days. Plasma determinations were performed after the first dosing at 0, 15, 30, 60, 90, 120, 180, 240, 300, and 360 min. A noncompartment analysis model for extravascular absorption was used for the pharmacokinetic analysis. To obtain the area under the concentration-time curve (AUC) within the "therapeutic window" of 1,000-1,200 microM x minutes a @entity1863 dose adjustment Was performed at the fourth dose. Forty-five @entity1863 pharmacokinetic analyses were performed in 34 @entity1 . Eleven @entity1 had their dose adjusted [1.19 +/- 0.14) mg/kg] at the fourth dose and the AUC was monitored at the fifth one. The mean AUC +/- SD after the fifth dose (998.1 +/- 189.2 microM x min) was different (p = .006)from that after the first dose (1 mg/kg) (687.63 +/- 166.43 microM x min). Six @entity1 had their first AUC into the "therapeutic window," 17 @entity1 had their dose adjusted [1.2 (+/- 0.22) mg/kg], but the "adjusted" AUC was not available. These data suggest that it may be reasonable to recommend a @entity1863 dose of 1.2 mg/kg to achieve the accepted therapeutic target in @entity1 undergoing BMT.

Therapeutic monitoring of XXXX in pediatric bone marrow transplantation.

@entity1 :: ('9606', 'Species') :: ['children'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan', 'Busulfan']
@entity1863 :: (MESH:D002066,Chemical) :: ['busulfan']
